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Abstract:  The pathogenesis of psoriasis is unknown, although it is generally accepted that 
this chronic inflammatory skin disorder is a complex autoimmune condition similar to other 
T-cell mediated disorders. Psoriasis imposes a heavy burden on the lifestyle of those affected 
due to the psychological, arthritic, and cutaneous morbidities; thus significant research has 
focused on the genetic and immunologic features of psoriasis in anticipation of more targeted, 
efficacious, and safe therapies. Recently, CD4+ T helper (Th) 17 cells and interleukins (IL)-12 
and -23 have been important in the pathogenesis of T-cell mediated disorders such as psoriasis 
and has influenced the development of medications that specifically target these key immuno-
logical players. Ustekinumab is a monoclonal antibody belonging to a newly developed class of 
biological, anti-cytokine medications that notably targets the p40 subunit of both IL-12 and -23, 
both naturally occurring proteins that are important in regulating the immune system and are 
understood to play a role in immune-mediated inflammatory disorders. Ustekinumab’s safety 
and efficacy has been evaluated for the treatment of moderate-to-severe plaque psoriasis in 
3 phase III clinical trials, 2 placebo-controlled (PHOENIX 1 and 2), and 1 comparator-controlled 
(ACCEPT) study which proved advantageous in patients who were treatment-naive, previously 
failed other immunosuppressive medications including cyclosporine or methotrexate, were 
unresponsive to phototherapy, or were unable to use or tolerate other therapies. Ustekinumab 
has also been investigated for other indications such as psoriatic arthritis, Crohn’s disease, and 
relapsing/remitting multiple sclerosis. We present a concise review evaluating the evidence that 
supports the use of ustekinumab in the treatment of plaque psoriasis and other conditions.
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Introduction to management issues  
and role of ustekinumab
Psoriasis is a chronic inflammatory disease characterized by well-circumscribed, 
  erythematous plaques primarily affecting extensor skin surfaces due to an overpro-
duction of basal keratinocytes.1 Moderate-to-severe cutaneous involvement can be 
burdening, as the condition can progress to cover a large body surface area includ-
ing uncommon locations such as the hands and feet, genitals, and scalp. Symptoms 
of itching, burning, stinging, sensitivity, pain with associated bleeding, exudation, 
and skin scaling may be commonplace and cause difficulty sleeping, depression, 
and anxiety.2,3 About 10% to 30% of patients have associated psoriatic arthritis, 
a progressive, inflammatory arthropathy characterized by joint pain, swelling, and 
deformity; the frequency of psoriatic arthritis in persons with all types of psoriasis 
vary widely according to the nature of the diagnostic criteria, ascertainment used, Therapeutics and Clinical Risk Management 2010:6 124
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and study population.4 Early detection and treatment is 
crucial, as this may block the further progression of joint 
damage. Classic joint symptoms such as swelling, warmth, 
and pain with associated restricted range of motion may 
limit work duties or daily activities which can significantly 
impair a person’s quality of life. Conventional therapies for 
psoriatic arthritis include: non-steroidal anti-inflammatory 
medications (NSAIDs), systemic corticosteroids, disease-
modifying antirheumatic drugs (DMARDs) including 
methotrexate, sulfasalazine and/or leflunamide, and 
  biological agents.
Ustekinumab (formerly CNTO 1275; Stelara™; Centocor 
Inc., Horsham, PA, USA) is a newly developed, targeted mono-
clonal antibody directed against the common p40 subunit of 
interleukin (IL)-12 and IL-23; both are naturally occurring 
proteins that regulate specific components of the immune 
system. Both IL-12 and IL-23 have been associated with the 
pathogenesis of psoriasis, in part due to their relationship to 
the differentiation of naïve T-cells into Th1 and Th17 cells5,6 
(Figure 1). Th cells are a distinct subset of T-cells expressing 
unique characteristic cytokines each involved in mediating 
specific immune responses. As a newly developed, targeted 
biological agent, ustekinumab has demonstrated superior 
efficacy and safety in the treatment of plaque psoriasis by 
its unique mechanism of inhibiting IL-12/23 inflamma-
tory pathways.7 IL-23 stimulates survival and proliferation 
of Th17 cells, a key cell that regulates the production of 
other inflammatory cytokines (IL-17, IL-22, IL-21, IL-6, 
tumor necrosis factor (TNF)-α) and is overproduced in 
dendritic cells and keratinocytes found psoriatic plaques.8,9 
Th1 cells develop from naïve T-cells after exposure to 
IL-12, characteristically express the transcription growth 
factor (TGF)-β, and are defined by a specific set of pro-
inflammatory cytokines they produce (interferon(IFN)-γ, 
TNF-α, IL-2).10 It is becoming clearer that psoriasis is primar-
ily due to a complex interaction of particular immune cells 
and inflammatory cytokines, with Th17 cells and IL-12 and   
IL-23 playing a critical role. Understanding of these immune 
IL-12 IL-23
No Th 1 Signaling
(TNF-α, IFN-γ, IL-2)
No Th 17 Signaling
(IL-6,-17,-21,-22, TNF-α, IFN-γ)
IL-12Rβ1 IL-12Rβ2 IL-12Rβ1 IL-23R
ustekinumab ustekinumab
Figure 1 Ustekinumab, a human monoclonal antibody, works by inhibiting the similar p40 subunit of the proteins IL-12 and IL-23. Both IL-12 and IL-23 proteins are necessary 
to activate a cascade of inflammatory mediators responsible in the pathogenesis of psoriasis. Ustekinumab’s inhibition of the IL-12/23 pathway produces a profound suppression 
of both the Th1 and Th17 cell lineage of cytokines and chemokines resulting in a dramatic clearance of psoriasis.Therapeutics and Clinical Risk Management 2010:6 125
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cascade complexities may influence how we treat T-cell 
influenced inflammatory conditions, such as psoriasis, in the 
future. In recent years, biologics have changed the treatment 
of psoriasis, giving dermatologists additional therapeutic 
options that are potentially less toxic to the liver, kidneys, 
and bone marrow, and are not teratogenic compared to the 
traditional systemic therapies for psoriasis (acitretin, metho-
trexate, and cyclosporine). Nevertheless, traditional systemic 
therapies continue to play an important role in the treatment 
of psoriasis with their oral route of administration and low 
cost (compared with biologics) making them an important 
treatment option in the appropriate patient. A physician with 
notable experience is needed for all systemic therapies used to 
treat psoriasis, as they necessitate patient education, frequent 
laboratory testing and monitoring, and regular office visits. 
Phototherapy is very efficacious, but requires a heavy time 
commitment, a phototherapy unit, may increase the risk of 
skin cancer, and involves the diligence of a physician who 
has experience making frequent use of this therapy. Those 
who are unable to tolerate conventional therapies or who 
have failed other treatments will be of the highest necessity 
for more safe and effective treatments. Newly developed 
biological agents such as ustekinumab have grown increas-
ingly popular for the treatment of moderate-to-severe disease, 
as clinical studies have shown these agents to be free of the 
major organ toxicities of methotrexate and cyclosporine, and 
successful in treating those who may have been unresponsive 
or unable to tolerate traditional therapies (Table 1). Still, 
the biological agents have specific contraindications and 
potential side effects, as these medications are inherently 
immunosuppressive and long-term efficacy and safety is still 
relatively unknown. Ustekinumab was recently approved 
in the United States (September 2009) for the treatment 
of moderate-to-severe plaque psoriasis, and has already 
been marketed in Canada (December 2008) and Europe 
(January 2009). Ustekinumab has also been evaluated for 
its role in treating psoriatic arthritis, Crohn’s disease, and 
RRMS. Any condition whose pathogenesis involves the 
IL-12/23 pathways has the potential to respond to treatment 
with this medication.
Table 1 Biological agents available for the treatment of psoriasis
Generic name Trade name Description Dosing Other  
indications
Year of 
United States 
approval
Anti-TNF-α agents
Etanercept Enbrel71 Dimeric fusion 
protein
50 mg SC BIW for 3 months, 
followed by a reduction to a 
maintenance dose of 50 mg  
SC per week
RA, JIA,  
PsA, AS
2004
Adalimumab Humira72 Human monoclonal 
antibody
80 mg SC × 1, followed by  
40 mg SC EOW starting  
one week after initial dosage
RA, JIA, PsA,  
AS, CD
2008
Infliximab Remicaide73 Chimeric monoclonal 
antibody
5 mg/kg given as an IV  
infusion, followed by 
additional doses at 2 and 6 
weeks after the first infusion, 
then every 8 weeks thereafter
RA, CD, PsA,  
AS, UC
2006
Anti-T-cell agents
Alefacept Amevive74 Dimeric fusion 
protein
15 mg IM given once weekly 
for 12 weekly injections
None 2003
Anti-cytokine  
agents
Ustekinumab Stelara68 Human monoclonal 
antibody
45 mg (if patient 100 kg) 
or 90 mg (if patient 100 kg) 
SC × 1, followed by a second 
dose administered four weeks 
after the initial dose, with 
subsequent doses given every 
12 weeks thereafter
None 2009
Abbreviations: TNF, tumor necrosis factor-α; RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; SC, subcutaneous; mg, milligram; kg, kilogram; BIW, twice weekly; 
CD, Crohn’s disease; EOW, every other week; UC, ulcerative colitis; IV, intravenous; IM, intramuscular.Therapeutics and Clinical Risk Management 2010:6 126
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Review of pharmacology  
and mode of action
Th1 cells predominate in the skin and synovial fluid of 
  psoriasis patients and give rise to pro-inflammatory cytokines 
TNF-α, IFN- γ, and IL-2; all of which are major components 
that activate antigen-presenting cells and macrophages to 
induce T-cell activation.7,11,12 More recently, Th17 cells have 
been recognized as a distinct lineage of pro-inflammatory 
Th cells essential for the pathogenesis of autoimmune dis-
ease.13 IL-1β is required to activate a naïve T-cell down the 
Th17 pathway. In mice, commitment to the Th17 lineage is 
dependent on TGF-β, IL-6, and IL-23, resulting in Th17 cell 
expression of IL-6, IL-17, IL-21, IL-22, IFN-γ, chemokine 
ligand (CCL) 20, transcription factor RORγ, and TNF-α. 
IL-17 plays a critical role in epithelial defense, while IL-22 
promotes epidermal hyperproliferation and keratinocyte 
proliferation and host defense proteins.14,15 Th1 cells require 
IL-12 to support development, whereas Th17 cells depend 
on the presence of IL-23 to properly function. Many reports 
show that IL-12 and IL-23 play key roles in the develop-
ment of psoriasis, in part due to their relation to both the 
  stimulation of the innate and adaptive immune systems. 
In a mouse study, direct intradermal injections of IL-23 into 
normal skin produced erythematous, thick, scaly lesions 
that  demonstrated a mixed dermal infiltrate and epidermal 
hyperplasia with associated with parakeratosis reminiscent 
of psoriatic plaques on histological analysis; although, 
injection with IL-12 in similar matter failed to induce 
the same response.16 The authors concluded that IL-23 is 
important in the development of psoriasis. Another study 
confirmed that IL-23 is an important cytokine is involved 
in the development of IL-17 producing Th17 cells.15 These 
authors showed that IL-22 is preferentially produced by 
Th17 cells and mediates the acanthosis induced by IL-23. 
It was concluded that Th17 cells, through the production of 
both IL-22 and IL-17, might have essential functions in host 
defense and in the pathogenesis of autoimmune diseases such 
as psoriasis. IL-22 appears to be a downstream mediator of 
psoriatic inflammation by mediating the communication 
between the immune system and epithelial cells.17 IL-17 is 
more pro-inflammatory, while IL-22 retards keratinocyte 
  differentiation. IL-22 is also increased in psoriatic lesions and 
in plasma and these levels correlate with disease severity.18 
Multiple reports have also implicated the IL-23 dependent 
IL-22, but not IL-17 production, in protective immunity to 
infection with gram-negative organisms such as Salmonella 
enteritidis in the respiratory and digestive epithelium.19–21 
Recently, a Th22 cell subpopulation (characterized by the 
secretion of IL-22 and TNF-α) was identified in the epidermis 
of individuals with psoriasis.22 Th22 clones derived from 
patients with psoriasis were stable in culture and exhibited 
a profile clearly separate from those of Th1, Th2, and 
Th17 cells. These pro-inflammatory Th22 responses were 
synergistically dependent on IL-22 and TNF-α. The authors 
concluded that the human Th22 subset may represent a sepa-
rate T-cell division with a distinct identity with respect to gene 
expression and function, present within the epidermal layer 
in inflammatory skin diseases. Further, it was demonstrated 
that psoriasis mediators IL-17 and IL-22 synergistically 
induce the production of IL-20 subfamily proteins in cul-
tured human keratinocytes and the expression of the IL-22 
receptor (IL-22R) was also increased in epidermal lesions 
versus normal skin.23 IL-17 and IL-22 coordinately enhanced 
cytokine, chemokine, and growth factor production depend-
ing on the amount of IL-22R expression. The data concluded 
that increased IL-22R expression in epidermal keratinocytes 
contributes to the pathogenesis of psoriasis through enhanc-
ing the coordinated effects of IL-22 and IL-17.
Ustekinumab therapy rapidly decreased expression of a 
variety of pro-inflammatory cytokine genes in psoriatic skin 
lesions including p19, p40, and IL-17A.24 Recent evidence 
also suggests that efficacy from TNF-α antagonist therapy 
may be similar to the mechanism of ustekinumab by down-
regulating pro-inflammatory pathways in lesional skin.25,26 
Etanercept reduced the inflammatory dendritic cell products 
that drive Th17 cell proliferation (IL-23), as well as Th17 cell 
products and downstream effector molecules (IL-17, IL-22, 
CCL 20, and beta-defensin 4). This study suggested a role 
for Th17 cells in addition to Th1 cells in the pathogenesis of 
psoriasis. Th17 cells may be particularly important in driving 
epidermal activation in psoriatic plaques, whereas Th1 cells 
must also be eliminated for final disease resolution.
It is suggested that certain genetic alteration of the IL-23 
(p40 and p19) or IL-12 (p40 and p35) subunits as well as the 
IL-23 receptor or its ligand will lead to enhanced IL-23 pro-
duction and subsequent psoriasis susceptibility. In contrast, 
other mutations that decrease IL-23 or IL-12 will give protec-
tion from psoriasis.27–29 Altogether, these findings indicate 
that genes participating in IL-12/23 signaling play a signifi-
cant role in the pathogenesis of chronic epithelial inflamma-
tion as seen in psoriasis. In humans, IL-23 is clearly elevated 
in psoriatic lesions as indicated by increased levels of both 
p19 and p40 (subunits of IL-23) mRNA in lesional skin as 
compared to non-lesional skin, but the mRNA levels of p35 
(subunit of IL-12) are not.30 These data suggest that IL-23 
appears to play a more dominant role than IL-12 in psoriasis. Therapeutics and Clinical Risk Management 2010:6 127
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Immunohistochemical analyses have revealed p40 and p19 
(subunits of IL-23) protein expression in dermal dendritic 
cells and keratinocytes of lesional psoriatic skin.31,32 Genetic 
studies have shown that a single nucleotide polymorphism in 
p40 (the common subunit of both IL-12 and IL-23)33 as well 
as polymorphisms in the gene encoding p1934 (IL-23 specific) 
was associated with the development of psoriasis.
IL-17A mRNA is elevated in psoriatic skin when 
  compared to non-lesional skin35 and immunohistochemical 
staining for IL-17A positive T-cells has also been reported.36 
These authors concluded that human and mouse Th17 cells 
require distinct factors during differentiation and that human 
Th17 cells may regulate innate immunity in epithelial 
cells. IL-23 and IL-1β induced the development of human 
Th17 cells from naïve T-cells. IL-12 and IL-23 both share 
a common p40 subunit which is the target for the human 
monoclonal antibody ustekinumab. Ustekinumab does not 
  associate with p35 subunit of IL-12 or the p19 subunit of 
IL-23, thus future medications may utilize these distinctions. 
This mechanism allows for the inhibition of naïve   
T-cells, which requires IL-12 and IL-23 for differentiation, 
  proliferation, and effector function. Subsequently, both 
Th1 and Th17 cells and their pro-inflammatory cytokines 
are reduced resulting in marked efficacy and safety in the 
treatment of psoriasis.37
Efficacy studies
Plaque psoriasis
In early clinical studies on ustekinumab, confirmable 
results were seen after both intravenous and subcutaneous 
administration of the drug (Table 2). In the first-in-human, 
non-randomized, open-label study of intravenous doses of 
anti-IL-12/23, 18 subjects with at least 3% body surface 
area involvement were enrolled in four dose groups (0.1, 
0.3, 1.0, and 5.0 mg/kg) to evaluate safety, efficacy, and 
  pharmacokinetics.37 Twelve of 18 subjects (67%) achieved 
at least a 75% improvement in Psoriasis Area and Severity 
Index (PASI) between weeks 8 and 16 after study agent 
administration. Anti-IL-12 was well tolerated with no 
related serious adverse events or infusion reactions reported. 
The authors concluded that significant and sustained con-
centration-dependent improvement was observed in most 
subjects.
In another phase I study, the pharmacokinetics, 
  pharmacodynamics, and clinical response of single 
  subcutaneous administrations of anti-IL-12/23 was evaluated 
in 21 subjects.38 Subjects were enrolled sequentially into 
four dose cohorts (0.27, 0.675, 1.35, and 2.7 mg/kg) and 
  randomized to anti-IL-12/23 or placebo in a 4:1 ratio and 
evaluated through 24 weeks. Mostly mild adverse events and 
no serious adverse events were reported. Of the 17 subjects 
who received the IL-12/23 monoclonal antibody, 13 (76%) 
achieved PASI 75, compared with no placebo subjects. 
mRNA expression of IL-12, IL-23, IL-8, IL-18, and IFN-γ 
in psoriatic plaques decreased in subjects with sustained 
PASI improvement.1,7 The authors concluded that a single 
  subcutaneous administration of IL-12/23 monoclonal 
antibody was well tolerated and showed excellent clinical 
response in subjects with moderate-to-severe psoriasis.
A double blind, placebo-controlled, phase II study fur-
ther examined the role of ustekinumab in 320 patients with 
  moderate-to-severe plaque psoriasis.39 Patients were assigned 
to receive ustekinumab at four varying subcutaneous dos-
ages (one 45 mg dose, one 90 mg dose, four weekly 45 mg 
doses, four weekly 90 mg doses, or placebo). Patients were 
evaluated at weeks 12 and 24 for efficacy. Patients assigned 
to medication received one additional dose at week 16 if 
needed and those assigned to placebo crossed over to receive 
one 90 mg dose at week 20. PASI 75 was achieved at week 
12 in 52% of patients who received 45 mg, 59% of those 
who received 90 mg, 67% of those who received four weekly 
45 mg doses, and in 81% of those who received four weekly 
90 mg doses, as compared with 2% of those who received 
placebo. Strikingly, there were PASI 90 scores identified 
in 23%, 30%, 44%, and 52% respectively, of patients who 
received the medication, as compared with 2% of patients 
who received placebo. PASI response rates correlated with 
the Physician’s Global Assessment (PGA) scores. Further, 
as early as 2 weeks into therapy, notable improvements in 
psoriasis signs and symptoms were reported and patients 
experienced a significant improvement in quality of life 
scores.1,39
The longer-term efficacy and safety of ustekinumab has 
been evaluated in two major phase III studies in which treat-
ment medication was compared with placebo.40,41 Both stud-
ies were powered to detect whether ustekinumab was more 
effective than placebo and all efficacy data were analyzed 
according to the assigned treatment group (intention-to-treat 
population [ITT]), while all the safety data were analyzed 
according to the actual treatment received. Previous biological 
therapy had been given to approximately half of the patients 
in PHOENIX 1 and approximately one third of patients in 
PHOENIX 2. The trial designs were complicated and con-
sisted of 3 phases: 1) random assignment, where patients 
were dosed with placebo or treatment medication; 2) cross-
over, where patients initially assigned to placebo were then Therapeutics and Clinical Risk Management 2010:6 128
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switched to treatment medication; and 3) re-randomization, 
where responders (PHOENIX 1) were re-randomized to 
active or placebo treatment or where partial responders 
(PHOENIX 2) were randomized to dose intensification (every 
8 weeks) or continued treatment (every 12 weeks).
In PHOENIX 1,40 766 patients were randomized to 
receive subcutaneous injections of ustekinumab 45 mg or 
90 mg at weeks 0 and 4, followed by the same dose every 
12 weeks; or placebo at weeks 0 and 4 and then crossed over 
to receive ustekinumab 45 mg or 90 mg at weeks 12 and 
16, followed by dosing every 12 weeks. Patients who were 
originally randomized to ustekinumab and achieved a PASI 
75 response at both weeks 28 and 40 were re-randomized 
at week 40 to maintenance ustekinumab or withdrawn from 
treatment (assigned to placebo) until loss of response (loss of 
at least 50% PASI improvement). Patients not achieving PASI 
75 at weeks 28 or 40 were not re-randomized and their dosing 
was discontinued or modified. Baseline randomization was 
stratified by investigational site, weight (90 kg or 90 kg), 
and the number of conventional systemic therapies to 
which patients had an inadequate response, intolerance, or 
contraindication (3 or 3). Week 40 randomization was 
stratified by investigational site and baseline weight (90 kg 
or 90 kg).
Significantly more patients in the ustekinumab treatment 
groups achieved the primary endpoint of a PASI 75 at week 
12: 67.1% of patients receiving 45 mg ustekinumab, 66.4% 
of patients receiving 90 mg ustekinumab, and 3.1% of those 
receiving placebo (Figure 2). The onset of efficacy was rapid, 
with a higher proportion of patients in the ustekinumab-
treated group achieving PASI 50 by week 2 and PASI 75 
by week 4. By week 12, PASI 50 was achieved by 83.5% 
of patients receiving 45 mg ustekinumab, 85.9% receiving 
90 mg ustekinumab, and 10.2% receiving placebo. Cleared 
(0) or minimal (1) disease based on the PGA was achieved 
in significantly more patients having active treatment (60.4% 
in ustekinumab 45 mg group, 61.7% in ustekinumab 90 mg 
group, and 3.9% in placebo group). Improvements in PASI 
scores were paralleled by the Dermatology Life Quality 
Index (DLQI), indicating that psoriasis improvement had a 
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positive effect on patient’s quality of life. These values were 
  maintained in patients in the treatment groups as opposed 
to the worsening scores seen in those withdrawn from treat-
ment.
Enhanced efficacy was observed throughout the active 
treatment phase (after the placebo-controlled portion of the 
study), with a maximum effect noted at week 24 for both dos-
ing groups (PASI 75 in 76.1% and 85.0% of the 45 mg and 
90 mg groups respectively). Similar PASI values were noted 
in placebo subjects crossed over to ustekinumab treatment 
at week 12. More than 90% of patients in both ustekinumab 
groups achieved PASI 50 and about half of patients in both 
ustekinumab groups achieved at least a PASI 90 at week 
28 (Figure 3). Greatest responses were seen in patients who 
were originally allocated placebo and then randomized to 
ustekinumab 90 mg and these responses were maintained 
through week 40.
Among patients re-randomized at week 40 to either 
treatment or placebo, maintenance of PASI 75 (ie, time to 
loss of PASI 75 response) was better in patients receiving 
maintenance therapy than in those withdrawn from therapy. 
PASI scores were steady through week 76 in the maintenance 
group, whereas the withdrawal group progressively has 
deterioration of PASI scores by week 44 (16 weeks after 
withdrawal) with acceleration of loss noted after week 52. 
The median time to loss of PASI 75 after withdrawal was 
close to 15 weeks, with no reports of rebound psoriasis. The 
improvements declined from 96% at week 40 to about 40% 
at week 64 (about a 56% loss). Upon re-initiating treatment 
(195 patients), 85.6% regained PASI 75 within 12 weeks. The 
DLQI responses also worsened in patients withdrawn from 
therapy. Overall, PASI 75 response was better maintained to 
at least one year in those receiving maintenance ustekinumab 
than in those withdrawn from treatment at week 40. Adverse 
events were minimal, suggesting that treatment with 
ustekinumab was safe and effective for at least one year 
when administered every 12 weeks. In general, side effects 
did not require treatment adjustment, did not appear to be 
dose-related, and were not considered serious. Nonetheless, 
the size and duration of the trial do not rule out the potential 
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for long-term, unforeseen side effects upon exposure of 
the medication to larger patient populations over longer 
  durations.
In PHOENIX 2,41 1230 patients who were randomized to 
receive ustekinumab 45 mg or 90 mg at weeks 0, 4, and every 
12 weeks, or placebo at weeks 0 and 4 with half randomized 
to crossover to receive ustekinumab 45 mg and the other half 
to 90 mg at weeks 12, 16, and every 12 weeks thereafter. 
Partial responders (patients achieving PASI 50 but 75) 
were re-randomized at week 28 to continue dosing every 
12 weeks or escalate to dosing every 8 weeks. Patients not 
achieving PASI 50 at week 28 discontinued treatment and 
patients achieving PASI 75 at week 28 continued to receive 
the study drug every 12 weeks. The primary efficacy endpoint 
was the proportion of PASI 75 responders at week 12. 66.7% 
of patients receiving 45 mg ustekinumab and 75.7% of 
patients receiving ustekinumab 90 mg compared to 3.7% of 
patients receiving placebo achieved a PASI 75 response at 
week 12. A PGA of cleared (0) or minimal (1) psoriasis was 
seen in 68.0% of those treated with ustekinumab 45 mg and 
73.5% of those treated with 90 mg compared with 4.9% of 
placebo, indicating a significant response in those treated with 
ustekinumab. Significant improvements in patient-reported 
outcomes based on decreases in the DLQI scores were seen 
in both ustekinumab groups. DLQI scores of 0 or 1 were 
seen in 55.3% and 56.4% of ustekinumab 45 mg and 90 mg 
groups respectively, compared to 3.2% on placebo. Efficacy 
was noted as early as week 2 (as measured by PASI 50) and 
most evident by week 4 (as measured by PASI 75). Interest-
ing to note, at week 12 there were only few non-responders 
(PASI 50): 16.4% of those receiving ustekinumab 45 mg 
and 10.7% of those on ustekinumab 90 mg compared to 90% 
of those taking placebo.
PASI 75 responses continued to increase after the 
  placebo-controlled phase, with a maximum response noted 
at week 20 (74.9% in ustekinumab 45 mg group and 83.5% 
in ustekinumab 90 mg group). After cross over to active 
treatment, the response rates in the placebo to ustekinumab 
groups were similar to those seen in individuals originally 
randomized to ustekinumab. By week 28, PASI 75 rates were 
69.5% to 78.5%, while PASI 50 rates were over 92%. Only 
5% to 7% of all ustekinumab-treated patients attained less 
than a PASI 50 response. PGA was cleared (0) or minimal 
(1) in 61% to 70% of patients. The greatest response rate was 
seen in those patients switched from placebo to ustekinumab 
90 mg, as also seen in PHOENIX 1.
Patients who were PASI 75 responders at week 28 
  continued to receive the study drug every 12 weeks until 
week 52, with all clinical responses sustained until week 52. 
At week 52, the median percent improvement from baseline 
in PASI was 95.3% in the 45 mg group and 95.6% in the 
90 mg group. Partial responders at week 28 were seen in 
22.7% of those treated with ustekinumab 45 mg and 15.8% 
of those treated with ustekinumab 90 mg. These patients were 
more likely to have a higher body weight, more marked or 
severe disease as measured by PGA, have a higher incidence 
of psoriatic arthritis, and have a longer duration of psoriatic 
disease. More of the partial responders had used conventional 
systemic agents and were more likely to have failed treatment 
with at least on conventional systemic or biological agent 
than the responders. A higher percentage of partial respond-
ers (12.7%) had neutralizing antibodies against ustekinumab 
than PASI 75 responders (2.0%) and they were more likely 
to have lower (two to three times) ustekinumab serum levels 
than responders (0.72 µg/mL in PASI 75 responders treated 
with 90 mg ustekinumab versus 0.39 µg/mL in the 45 mg 
ustekinumab group versus 0.14 µg/mL in partial responders) 
at week 28. A small proportion of partial responders were 
identified in the study where dose escalation from 90 mg 
every 12 weeks to 90 mg every 8 weeks led to significant 
improvement, nearly doubling the PASI 75 response rate 
(68.8% versus 33.3%) by week 52. Although an improvement 
in response rate was not observed in partial responders who 
were escalated from 45 mg every 12 weeks to 45 mg every 
8 weeks. Overall, partial responders at week 28 performed 
better when given dosages of 90 mg every 8 weeks when 
compared to either 45 mg frequency and/or dosing every 
12 weeks. Dose intensification resulted in four to five times 
increase in mean trough serum drug concentrations in partial 
responders between weeks 28 and 52 (mean 0.70 µg/mL 
in the 45 mg group, 1.45 µg/mL in the 90 mg group). The 
conclusion was that ustekinumab at higher dosages (90 mg 
versus 45 mg) and for shorter intervals (8 weeks instead 
of 12 weeks) may be of benefit for patients who are partial 
responders. The efficacy data were obtained by non-responder 
imputation (NRI) analysis on the ITT population. This kind 
of analysis is considered a conservative method, so the out-
standing long-term efficacy rates yielded by those studies 
could possibly be underestimation of the real potential of 
this IL-12 and IL-23 inhibitor.42
Adverse event reporting was not significantly different 
for patients treated with placebo or either of the ustekinumab 
doses. Upper respiratory tract infection, nasopharyngitis, 
headache, and arthralgias were the most common. During 
the placebo-controlled phase, the number of infections was 
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improvement of overall skin response and quality of life 
in patients with both psoriasis and psoriatic arthritis. 
Throughout the studies, there were sustained improvements 
from baseline in the DLQI surveys in each group receiving 
ustekinumab compared with placebo.
The long-term side effects of ustekinumab are unknown 
and the majority of answers will come from post-marking 
studies and physician experience. Adverse events reported 
in clinical trials have been relatively mild, with the majority 
of events including susceptibility to mild infections such as 
nasopharyngitis and upper respiratory tract infection. Rates 
of infection were not higher in ustekinumab-treated patients 
when compared to placebo treated patients over 12 weeks 
of therapy. In the phase II trial, the frequency and character 
of adverse event rates were similar between the two groups; 
79% of treated patients and 72% of placebo patients reported 
adverse events, while 43% in the treated group and 39% in 
the placebo group reported minor infections. In the phase III 
studies, adverse events did not require discontinuation of 
therapy, although in real practice physicians may chose 
to hold dosing or discontinue therapy for a short time if a 
patient has recurrent or moderate-to-severe adverse events. 
In all ustekinumab studies, rates of serious infections, car-
diovascular events, injection site reactions, and malignan-
cies were low and the drug was well tolerated by patients. 
Serious adverse events in the ustekinumab group included 
2 patients hospitalized for infections, 2 cases of myocardial 
infarction, 1 case of a cerebrovascular accident, 2 patients 
diagnosed with non-melanomatous skin cancer, and 1 case 
of prostate cancer. Interestingly, higher ustekinumab dosing 
did not appear to increase the infection rate in those treated. 
In the placebo group, 2 serious adverse events were reported: 
1 case of basal cell carcinoma and 1 case of severe psoriasis 
exacerbation that required hospital admission.
PHOENIX 1 and 2 studies both demonstrate is the 
ustekinumab gives a rapid, clinically significant (measured 
by PASI, PGA, and quality of life scores) improvement in 
patients with moderate-to-severe psoriasis, including those 
who had failed prior biological or conventional systemic 
therapies. Clinical responses were apparent by 2 weeks, with 
maximal response rates seen after about 6 months. These data 
lend support to the notion that IL-12 and IL-23 have a key role 
in the pathogenesis of psoriasis. These clinically meaningful 
improvements were seen in patients treated with ustekinumab 
and were paralleled by improvements in patient-reported 
outcomes. Over 80% of patients receiving ustekinumab had 
a PASI 50 response at week 12 and over 90% of all patients 
had a PASI 50 at week 28. The onset of action was seen within 
2 weeks of the first medication dosage and was maintained in 
patients who continued treatment every 12 weeks for up to 
76 weeks. The maintenance of efficacy between longer dosing 
intervals may be due to the fact that the pharmacodynamics 
effects of ustekinumab are longer than its pharmacokinetic 
effects.44 Further, the data suggest that a unique subset of 
partial responding patients could represent a distinct subset of 
patients who have key characteristics such as increased body 
weight, a longer history of psoriatic disease, have a history 
of psoriatic arthritis, and a greater resistance to biological 
agents. Symptoms gradually recurred in patients who therapy 
was withdrawn and quality of life improvements were lost, 
indicting the block of IL-12 and IL-23 is temporary and does 
not reverse the underlying causal mechanism of psoriasis. 
These observations suggest that maintaining response and 
quality of life improvements require continuous maintenance 
dosing. In patients withdrawn from ustekinumab, re-response 
could be restored with treatment within 12 weeks.
Partial responders represented a distinct subset of 
patients who had a higher body-weight, longer duration of 
psoriatic disease, had a history of psoriatic arthritis, and a 
greater resistance to biological and conventional systemic 
agents previously. Although this subpopulation had lower 
mean serum drug levels of ustekinumab than did patients 
who responded to treatment every 12 weeks, lower serum 
concentrations of ustekinumab alone do not completely 
explain their partial response. After dose intensification with 
45 mg in partial responders, trough drug concentrations were 
comparable with those achieved in the PASI 75 responders 
initially randomized to receive 90 mg; however, dose 
  intensification in the 45 mg group did not lead to an increase 
in clinical response. Thus, compared with responders, partial 
responders seemed to have disease that was more likely to be 
resistant to treatment. Nonetheless, this subpopulation does 
seem to have disease that is responsive to highest levels of 
ustekinumab, as evidenced by the dose intensification. These 
patients are more likely to respond to higher dosages (90 mg 
versus 45 mg) given more frequently (every 8 weeks versus 
every 12 weeks).
Ustekinumab was also studied in phase III multicenter, 
randomized, head-to-head study comparing ustekinumab and 
etanercept for the treatment of moderate-to-severe plaque 
psoriasis.44 Findings from this landmark study showed that 
ustekinumab demonstrated superior efficacy to etanercept 
in both primary (PASI 75 at week 12) and secondary (PGA 
score of cleared (0) or minimal (1) at week 12 and PASI 90 
at week 12) efficacy endpoints. The ACCEPT trial included 
903 patients (3:5:5 ratio; etanercept = 347, ustekinumab Therapeutics and Clinical Risk Management 2010:6 134
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45 mg = 209, ustekinumab 90 mg = 347) with chronic 
plaque psoriasis. Patients were randomized to receive either 
ustekinumab 45 mg or 90 mg subcutaneously at weeks 0 
and 4 or etanercept 50 mg subcutaneously two times per 
week for 12 weeks. The primary endpoint of the trial was 
the percentage of patients achieving a PASI 75 at weeks 
12. 68% and 74% of patients receiving ustekinumab 45 mg 
or 90 mg respectively achieved a PASI 75, compared with 
57% of patients receiving etanercept 50 mg subcutaneous 
injections twice weekly for 12 weeks (Figure 4). A greater 
proportion of patients in the ustekinumab 45 mg and 90 mg 
groups achieved a PGA of cleared (0) or minimal (1) (65% 
and 71%, respectively) compared to 49% of etanercept-
treated patients. PASI 90 was observed in 36% and 45% of 
patients in these respective ustekinumab groups versus 23% 
of etanercept-treated patients.
Among patients for whom conventional systemic 
  psoriasis therapies were inadequate or intolerable, there 
were contraindications to their usage, a greater proportions 
of patients in the ustekinumab-treated groups achieved 
PASI 75 responses when compared with patients in the 
etanercept-treated group. In patients who had one previous 
treatment of systemic, biologic, or phototherapy, 68% in 
the ustekinumab 45 mg group and 74% of patients in the 
ustekinumab 90 mg group achieved PASI 75, as compared 
to 57 % of the etanercept group. In patients with two previ-
ous treatments, 67% of the 45 mg group and 74% in the 
90 mg group achieved PASI 75, compared to 51% of the 
etanercept group. For those who had received three previous 
treatments, 55% of the 45 mg group and 72% of the 90 mg 
group reached PASI 75, compared to 39% in the etanercept 
group. Adverse events were experienced in less than 2% of 
patients receiving ustekinumab and included upper respira-
tory tract infection, arthralgia, headache, and infection (less 
than 1% were deemed serious). Further, 4 malignancies were 
noted in the ustekinumab group (3 in the ustekinumab 45 mg 
group and 1 in the ustekinumab 90 mg group) compared to 0 
in the etanercept-treated group. Injection site erythema was 
the most commonly reported event in the etanercept group 
(14.7%) and occurred with a greater frequency than that 
observed in the ustekinumab groups (combined 0.7%) and 
may have been influenced by the greater number of etanercept 
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injections required (up to 48 in the 12-week study) compared 
with ustekinumab (2 injections).
The overwhelming conclusion was that patients with 
moderate-to-severe psoriasis treated with two doses of 
either 45 mg or 90 mg ustekinumab demonstrated superior 
response, as measured by PASI and PGA when compared 
with patients treated with etanercept twice weekly for 
12 weeks. Additionally, ustekinumab and etanercept were 
generally well tolerated with comparable rates of adverse 
events. These data were presented as posters at the 17th 
meeting of the European Academy of Dermatology and 
Venerology in Paris, France, in September 2008 and the 67th 
Annual Meeting of the American Academy of Dermatology 
in San Francisco, California, in March of 2009.
Psoriatic arthritis
Ustekinumab was shown to have modest clinical improvement 
in a phase II study in patients with psoriatic arthritis.11 This 
study was a double-blind, randomized, placebo-controlled, 
crossover study at 24 sites in North America and Europe. 
Patients with active psoriatic arthritis were randomly assigned 
to either: ustekinumab (90 mg or 63 mg) subcutaneous every 
week for 4 weeks (weeks 0–3) followed by placebo at weeks 
12 and 16 (group 1); or placebo subcutaneous every week for 
4 weeks (weeks 0–3) followed by ustekinumab (63 mg) at 
weeks 12 and 16 (group 2). The primary endpoint was a 20% 
improvement in the American College of Rheumatology core 
set of measures (ACR20) at week 12. ACR20, ACR50, and 
ACR70 were determined in both groups at week 12. Groups 
1 and 2 demonstrated: 42% versus 14%, 25% versus 7%, and 
11% versus 0% for the respective ACR scores. ACR20 was 
maintained by 36% of patients treated only with ustekinumab 
throughout the trial for up to 32 weeks. As well, PASI 75 
was seen in 52% of those in group 1 versus 5% of those in 
group 2. During the placebo-controlled period (weeks 0–12), 
adverse events arose in 46 (61%) patients in group 1 and 44 
(63%) in group 2. Serious adverse events were recorded in 
3 (4%) group 2 patients and none (0%) in group 1; 1 case 
of myocardial infarction, 1 case of non-cardiac chest pain, 
and 1 case of hemorrhagic gastric ulcers. After week 12, 1 
case of a hemorrhagic abdominal cyst was reported by a 
group 2 patient who had not received ustekinumab at weeks 
12 and 16. Six other serious adverse events were reported 
through week 36, including cases of syncope, respiratory-
tract infection, hemorrhage, stroke, myocardial infection, 
and gastric ulcer. One case of malignant basal cell cancer 
occurred in an individual who had been previously diagnosed 
with two basal cell cancers.
The authors concluded that ustekinumab significantly 
reduced signs and symptoms of psoriatic arthritis, diminished 
skin lesions compared with placebo, and was well tolerated. 
Larger and longer term phase III studies are needed to 
definitively establish safety and efficacy in this population of 
patients. Nonetheless, results from this study are promising 
and suggest that treatment with ustekinumab can remain 
safe and effective for a long duration as well as maintain 
  improvements in physical function and quality of life.
Crohn’s disease
Crohn’s disease is an inflammatory condition of the bowel 
that is believed to be the result of an imbalance between pro-
inflammatory and anti-inflammatory mediators. 
  Unpredictable flares and remissions characterize the long-
term course of this illness. Conventional therapy includes 
systemic corticosteroids and other immunosuppressive 
  medications such as azathioprine, methotrexate, or 
  mycophenolate mofetil, anti-inflammatory medications such 
as sulfasalazine and mesalamine, and/or systemic antibiotics 
such as metronidazole and fluoroquinolones. A large number 
of patients may still experience active disease and require 
biological medications (eg, infliximab, adalimumab, and 
certolizumab pegol) for treatment as TNF-α, a key inflam-
matory cytokine and mediator of intestinal inflammation, 
is expressed prominently in inflammatory bowel disease. 
However, some patients may experience a primary non-
response or become intolerant to treatment. Thus, alternative 
treatments are needed for more safe and effective manage-
ment of inflammatory bowel disease.
IL-12/23 has also been implicated in the pathophysiology 
of Crohn’s disease; however the complex relationship between 
Th1 and Th17 cells has not been completely analyzed.45 It is 
thought that IL-23 may play important roles in controlling 
the differential of Th1/Th17 balance in both ulcerative colitis 
and crohn’s disease, although Th17 cells seem to exist in both 
diseases.46 Thus, ustekinumab was studied in a double-blind, 
cross-over trial of 104 patients with moderate-to-severe 
Crohn’s disease.47 Patients were randomly assigned to one of 
four groups: 1) subcutaneous placebo weekly at weeks 0–3 
then 90 mg at weeks 8–11; 2) subcutaneous 90 mg weekly 
at weeks 0-3 then placebo at weeks 8-11; 3) intravenous 
placebo at week 0 then 4.5 mg/kg at week 8; or 4) intrave-
nous 4.5 mg/kg at week 0 then placebo at week 8. Clinical 
response rates for the combined groups given ustekinumab 
and placebo were 53% and 30% respectively at weeks 4 and 
6, and 49% and 40% respectively at week 8. In a subgroup 
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primary nor secondary non-responders), clinical response 
to ustekinumab was significantly greater than the group 
given placebo through week 8. Overall, there were higher 
frequencies of clinical response, remission, and symptom 
improvements observed in those who received intravenous 
injections versus subcutaneous injections.
In the second part of this study, an open-label trial 
assessed the effects of four weekly subcutaneous injec-
tions of ustekinumab (90 mg weekly at weeks 0–3) versus 
one intravenous infusion of ustekinumab (4.5 mg/kg at 
week 0) in 27 patients who were either primary or gradual 
non-responders to infliximab. It was found that within this 
  subgroup, patients treated with ustekinumab rather than 
placebo achieved higher clinical response rates. Clini-
cal responses at week 8 to subcutaneous and intravenous 
ustekinumab were 43% and 54% respectively. Additionally, 
higher response and remission rates were observed with 
intravenous ustekinumab injections versus subcutaneous 
injections. There was no increase in the number of adverse or 
serious adverse events in patients given ustekinumab through 
week 8 compared with placebo. Overall, the placebo group 
experienced higher incidences of nausea, fatigue, and disease 
exacerbation while the treatment group experienced anxiety 
and pruritus. Adverse events such as pyrexia, flushing, and 
pruritus occurring under intravenous administration were 
mild and reported by 19% of ustekinumab patients and 0% of 
those receiving placebo. The rates of infections were similar 
between both treatment and placebo groups. Two serious 
infections occurred throughout the course of the trial: one 
case of disseminated histoplasmosis in a patient previously 
treated with infliximab concurrently taking immunosuppres-
sants and one case of viral gastroenteritis. Reported admin-
istration site reactions were mild and seen most commonly 
in patients receiving subcutaneous placebo (4%) compared 
patients receiving subcutaneous ustekinumab (0%).
The authors concluded that ustekinumab induced a 
clinical response in patients with moderate-to-severe Crohn’s 
disease, especially in patients previously given infliximab.
Relapsing/remitting multiple  
sclerosis (RRMS)
Multiple sclerosis is a complex neurological disorder of 
the central nervous system, characterized by recurrent and 
multifocal inflammation, demyelination, and axonal damage. 
The clinical manifestations include loss of visual, sensorimo-
tor, autonomic, and cognitive functions. Current available 
treatments are modestly effective (eg, IFN-ß and glatiramer 
acetate) or are intolerable long-term (eg, mitoxantrone and 
natalizumab).48 IL-12/23 have been strongly implicated in 
the pathogenesis of multiple sclerosis49 and in experimental 
autoimmune encephalomyelitis, an autoimmune disease 
which serves as a model for multiple sclerosis.50,51
Repeated subcutaneous injections of ustekinumab were 
tested in a recent study assessing safety, efficacy, and phar-
macokinetics in patients with RRMS. In this phase II, multi-
centered, randomized, double-blind, placebo-controlled study, 
249 patients with RRMS, patients were eligible to be equally 
and randomly assigned (based on study site and presence or 
absence of gadolinium-enhancing T1-weighted lesions at 
baseline) to one of five groups that received placebo or four 
different ustekinumab dosages at weeks 0–3, 7, 11, 15, and 
19. Ustekinumab doses were: 1) placebo subcutaneous every 
4 weeks; 2) 27 mg subcutaneous every 4 weeks; 3) 90 mg 
subcutaneous every 4 weeks; 4) 90 mg subcutaneous every 
8 weeks; 5) 180 mg subcutaneous every 4 weeks. The 90 mg 
subcutaneous every 8 weeks group received placebo substitute 
at weeks 7 and 15. The primary endpoint was the cumulative 
number of new gadolinium-enhancing T1-weighted lesions 
on serial cranial magnetic resonance imaging (MRI) through 
week 23 and patients were followed up through week 37. 
Ustekinumab treatment did not show a significant reduction 
in the primary endpoint for any dosage groups versus placebo. 
Due to the lack of demonstrated efficacy of ustekinumab 
in RRMS, the study was halted after week 37. At week 37, 
adverse events occurred in 38 (78%) placebo-treated patients 
and 170 (85%) ustekinumab-treated patients, with infections 
most commonly reported. Mild upper respiratory tract infec-
tions and nasopharyngitis were most commonly reported 
by approximately 50% of both placebo and ustekinumab 
groups. Headache, fatigue, and injection-site reactions were 
slightly higher in frequency among patients treated with 
ustekinumab (32%) versus placebo (14%). Serious adverse 
events occurred in one (2%) placebo-treated patient and six 
(3%) ustekinumab-treated patients; among those reported 
were flank pain, tonsil cancer, colon cancer, dyspnea, and 
rotator cuff syndrome. Malignant diseases were reported in 
two patients shortly after the initiation of ustekinumab treat-
ment; both patients were withdrawn from the trial and given 
appropriate treatment, which resulted in complete remission. 
The patient diagnosed with tonsil cancer had a history of 
smoking and was diagnosed with localized squamous cell 
carcinoma at week 20. The patient with colon cancer had pro-
gressive anemia which lead to a diagnosis of adenocarcinoma 
of the colon at week 16. No serious infections, cardiovascular 
events, or exacerbation of demyelinating events occurred. This 
study demonstrated that the use of an IL-12/23 neutralizing Therapeutics and Clinical Risk Management 2010:6 137
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antibody did not reveal therapeutic efficacy or inhibit the for-
mation of inflammatory white matter lesions in patients with 
RRMS.52 Although evidence from animal models supports 
the role of ustekinumab in the pathogenesis of autoimmune 
demylenating disease, therapeutic efficacy in this controlled 
clinical trial was not confirmed.
Safety and tolerability
The safety and tolerability of ustekinumab over several years 
is quite exceptional, although the long-term safety, efficacy, 
and tolerability remain to be determined. As of now, it 
appears as ustekinumab is safe and effective for short-term 
use in patients with Th1 and Th17 mediated conditions such 
as those described. More targeted therapies (eg, monoclonal 
antibody targeting of cytokines) for inflammatory condi-
tions appear (at this time) to have a better safety profiles 
  compared to those traditional therapies which globally 
suppress the immune system and can predispose patients 
to organ toxicity, infections, and cancers. Nonetheless, few 
long-term safety data on biological agents can refute or 
  support these claims.
Insight into the safety of the therapeutic targeting of 
particular cytokines comes from other diseases or genetic 
defects. Patients with hyper-IgE syndrome (Job’s syndrome) 
have been shown to have defects in Th17 cells (which produce 
IL-17 and -22), but not Th1 cells (which produce IFN-γ). 
These patients are prone to chronic Staphylococcus aureus 
abscesses, chronic candidiasis, and pulmonary infections.53–55 
IL-12 and Th1 cells are important in fighting infections as 
those with defects in p40 or in the IL-12 receptor subunit, 
IL-12Rβ1, are susceptible to intracellular bacterial infections 
like those caused by mycobacterial and S. enteriditis.56,57 A 
large homozygous deletion within the IL-12p40 subunit 
gene was found in a child with bacille Calmette-Guérin 
(BCG) and S. enteritidis infection, precluding expression of 
functional IL-12p70 cytokine by activated dendritic cells and 
phagocytes. As a result, IFN-γ production by lymphocytes 
was markedly impaired. This was the first discovered human 
disease resulting from a cytokine gene defect suggesting 
that IL-12 is essential to and appears specific for protective 
immunity to intracellular bacteria such as mycobacteria 
and Salmonella.58 Subsequently, this was supported by 
  experimental infections of knockout mice lacking IL-12 
or the IL-12 receptor and it was determined that IL-12, the 
signature IFN-γ-inducing cytokine, was crucial for protective 
immunity against intracellular microorganisms.59
Many individuals with genetic defects of IL-12/23-IFN-γ 
axis signal transduction, have been reported to have impaired 
ability to produce IFN-γ, an essential component of the Th1 
cytokine pathway which is responsible for clearing infections 
and intracellular bacteria.60 This transduction pathway has 
two major components, an IL-12/23 axis and an IFN-γ axis, 
that result in cellular activation to aid in the elimination of 
intracellular pathogens.61 An assortment of hypotheses are 
postulated regarding the mechanisms that invariably lead 
to susceptibility to mycobacteria and Salmonella infec-
tion such: 1) that IL-12 and IL-23 can induce TNF-α and 
  granulocyte-macrophage colony-stimulating factor (GM-
CSF) which can modulate INF-γ-independent activity; 2) 
that IL-12 and -23 have autocrine function on antigen-pre-
senting cells (APCs) which may have an additive effect on 
cytokine production and thus microbicidal mechanisms; and 
3) that IL-17, the production of with is stimulated by IL-23, 
but inhibited by IL-12 dependent immune mechanisms and 
is known to mediate inflammatory responses and play a 
role in the pathogenesis of various autoimmune disorders, 
function may be impaired. In summary, these mechanisms 
  unanimously suggest that IL-12/23 defects may skew the Th1/
Th2 signal transduction pathways important in protecting 
(and controlling) against various infectious agents; although 
future longitudinal studies will be needed to distinguish 
between these possibilities to delineate the role of IL-12 and 
IL-23 versus IFN-γ production in the resistance of various 
infectious etiologies. These disease-causing mutations of the 
IL-12/23-IFN-γ circuit were initially thought to be rare, but 
have now been reported in over 200 patients in a multitude 
of countries worldwide since 1996.62
Patients diagnosed with latent tuberculosis upon 
  screening were allowed into the phase III ustekinumab trials 
as long as they had received appropriate anti-tuberculous 
therapy. Thus far, no cases of tuberculosis, atypical myco-
bacterial, or Salmonella infections have been reported in 
patients treated with anti-IL12/23 antibodies. Nonetheless, 
as with other biological therapies, patients with a history of 
tuberculosis or those with latent disease should be closely 
monitored with yearly tuberculous skin testing, IFN-γ 
release assays, and/or chest X-ray and pulmonary referral 
when appropriate.63,64 Moreover, prior to treatment with 
anti-IL-12/23 therapy, patients with active or latent tuber-
culosis should be treated with appropriate anti-tuberculous 
therapy as the risk of tuberculous infections and the targeting 
of pro-inflammatory cytokines have not been completely 
elucidated. Further, the role of anti-IL-12/23 therapy in 
the development of malignancies is not yet known and 
will be an important issue to discuss in the future. There 
is some evidence that IL-12 has anti-tumor activity as the Therapeutics and Clinical Risk Management 2010:6 138
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systemic administration of IL-12 in mice leads to anti-tumor 
  activity7,65 and IL-23 may promote tumor formation.5 Lastly, 
while ustekinumab did not help in inhibiting RRMS, it is 
noteworthy that it did not create any neurological events as 
other biological agents, such as anti-TNF-α therapies, have 
been associated with new onset or exacerbation of central 
nervous system demyelinating disorders (some presenting 
with mental status changes and some associated with per-
manent disability) such as transverse myelitis, optic neuritis, 
and multiple sclerosis, as well as cases of new onset or exac-
erbation of seizure disorders. One case of reversible posterior 
leukoencephalopathy syndrome (RPLS) was observed in 
3523 ustekinumab-treated subjects. RPLS is a neurological 
disorder, which is not caused by demyelination or a known 
infectious agent and can present with headache, seizures, 
confusion, and visual disturbances. Conditions with which 
it has been associated include preeclampsia, eclampsia, 
acute hypertension, cytotoxic agents, and immunosup-
pressive therapy. The subject, who had received 12 doses 
of ustekinumab over approximately two years, presented 
with headache, seizures, and confusion. No additional 
ustekinumab injections were administered and the subject 
fully recovered with appropriate treatment.
Patient-focused perspectives
As demonstrated, the clinical data suggest that ustekinumab is a 
safe and effective agent in the short-term treatment of psoria-
sis and possibly other inflammatory conditions driven by the 
IL-12/23 pathways. In trials thus far, patients experienced sig-
nificant improvements in skin disease and symptoms, modest 
improvement in joint involvement, and sustained improve-
ments quality of life and health assessment disability scores.66 
Ustekinumab shows phamarcokinetic first-order elimination 
with a pharmacokinetic behavior typical of an IgG1-based 
monoclonal antibody and has a half-life of 3 weeks. This 
supports the infrequent dosing of every 12 weeks in patients 
with psoriasis.67 Infrequent dosing schedules, ease of 
administration, and long-term remissions make these newer 
monoclonal antibodies convenient and economical treatments 
options. The findings of the PHOENIX studies, suggest that 
ustekinumab can provide a new, highly effective and safe 
therapy for the treatment of moderate-to-severe psoriasis. 
Treatment with 2 subcutaneous injections of ustekinumab, 
followed by an injection every 12 weeks, led to PASI 75 
response in about three-quarters of patients, irrespective of 
dose. As approved, ustekinumab is dosed subcutaneously at 
weeks 0 and 4 and then every 12 weeks thereafter at a dos-
age of 45 mg per injection for patients 100 kg (220 lb) and 
90 mg per injection for patients 100 kg (220 lb). In subjects 
weighing 100 kg (220 lb), 45 mg was also shown to be 
efficacious, however, 90 mg resulted in greater efficacy.68 
The convenience of such infrequent dosing could positively 
affect adherence in psoriasis patients, who have historically 
shown poor adherence and low patient satisfaction. Dos-
ing flexibility up to 90 mg every 8 weeks might benefit the 
subgroup of patients who have treatment-resistant disease, 
while minimizing unnecessary drug exposure in the overall 
population.
Additionally, unlike the TNF-α blocking agents, the 
safety profile of ustekinumab as late does not limit its use in 
patients with a history of neurological disorders (such central 
nervous system demyelinating disorders), autoimmune 
  conditions, heart failure, or history of malignances (such 
as lymphoma), making it particularly unique. There have 
been few reports of serious infections such as bacterial, 
  mycobacterial, invasive fungal, viral, or other opportu-
nistic pathogens such as tuberculosis, histoplasmosis, 
aspergillosis, candidiasis, coccidioidomycosis, listeriosis, 
and pneumocystosis, as has been seen more commonly in 
patients on TNF-α blocking agents (typically with the con-
current use of methotrexate and/or systemic corticosteroids). 
Nonetheless, close clinical monitoring with laboratory test-
ing should be performed. Ustekinumab treatment has been 
associated with infections requiring hospitalization such 
as cellulitis, diverticulitis, osteomyelitis, gastroenteritis, 
pneumonia, and urinary tract infections. Patients deficient 
in IL-12/23 or defects of their pathway receptors have 
shown susceptibility to infections such as mycobacterium, 
Salmonella, and BCG vaccinations, thus routine diagnostic 
testing should be performed and dictated by close clinical 
monitoring. Finally, ustekinumab is an immunosuppres-
sant and theoretically has the ability to increase the risk of 
malignancies, although the safety of ustekinumab has not 
been evaluated in patients who have a history of malignancy 
or who have a known malignancy and the decision to do 
so should be proceeded with caution. Published literature 
showed that administration of murine IL-12 caused an anti-
tumor effect in mice that contained transplanted tumors 
and IL-12/23p40 knockout mice or mice treated with anti- 
IL-12/23p40 antibody had decreased host defense to 
tumors. Mice genetically manipulated to be deficient in both 
 IL-12 and IL-23 or IL-12 alone developed UV-induced skin 
cancers earlier and more frequently compared to wild-type 
mice.69,70 The relevance of these experimental findings in 
mouse models for malignancy risk in humans is unknown, 
although these findings may have future implications when Therapeutics and Clinical Risk Management 2010:6 139
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concomitantly treating a patient with phototherapy and 
anti-IL12/23 therapy. Further studies and poster-marketing 
surveillance will help to determine the longer-term safety 
of ustekinumab and other similar medications approaching 
(eg, briakinumab, formerly ABT-874).
Conclusions
Ustekinumab is a monoclonal antibody directed against 
the common p40 subunit of both IL-12 and IL-23 that has 
demonstrated superior efficacy and safety in the treatment 
of psoriasis. Evidence suggests that T-cell mediated 
  inflammatory conditions are influenced by IL-12 and IL-23 
resulting in skin disease secondary to a dysregulation of the 
immune system. Medications that suppress all or part of the 
immune system have a profound therapeutic effect as dem-
onstrated by this novel anti-cytokine targeted therapy. As 
more is learned about the pathogenesis of T-cell mediated 
skin conditions, targeted therapies that selectively block 
the pathogenic inflammatory pathways will offer advanced 
treatments for patients suffering with severe disease. Bio-
logical agents propose safe and effective alternatives to the 
traditional systemic therapies, although they are not without 
side-effects and the long-term safety and efficacy are not 
known. Supplementary investigations will be required to 
substantiate the full role of these therapies in the longer-
term treatment of T-cell mediated inflammatory conditions. 
Although we all agree on the need of more effective and 
safe therapies, we need to be cautious as there are many 
examples of therapies that were approved because of good 
evidence of efficacy and safety during clinical trials and 
then needed to be retired from the market because of seri-
ous side effects (eg, rofecoxib, efalizumab). For the time 
being, the excitement for ustekinumab and immunologically 
targeted therapies is well justified and offers new options 
for a diversity of patients.
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